Little Change Seen in Rates of ED Discharge After Acute Pulmonary Embolism
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 29, 2024 -- For patients with acute pulmonary embolism (PE), the rates of discharge from the emergency department were stable between 2012 and 2020, according to a study published online Jan. 30 in the Annals of Internal Medicine.
Nathan W. Watson, from Harvard Medical School in Boston, and colleagues examined whether the proportion of discharges from emergency departments for acute PE changed from 2012 to 2020 in a serial cross-sectional analysis. There were approximately 1,635,300 visits for acute PE between 2012 and 2020.
The researchers found that the emergency department discharge rates remained constant over time, with rates of 38.2 and 33.4 percent between 2012 and 2014 and between 2018 and 2020, respectively (adjusted risk ratio, 1.01 per year; 95 percent confidence interval, 0.89 to 1.14). None of the baseline characteristics predicted an increased likelihood of emergency department discharge, including established risk stratification scores; however, the likelihood of receiving oral anticoagulation at discharge was increased for patients at teaching hospitals and those with private insurance. Overall, 35.9, 33.1, and 34.8 percent of patients who were considered low-risk according to their Pulmonary Embolism Severity Index (PESI) class, simplified PESI score, and hemodynamic stability, respectively, were discharged from the emergency department setting.
"Our findings show that outpatient management seems to have remained relatively unchanged during that period and that a considerable proportion of low-risk patients are still managed with inpatient hospitalization," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-30 08:15
Read more
- Patients Living Outside Metropolitan Statistical Areas Travel Farther for Health Care Visits
- Clinical Practice Guidelines Updated for Primary Prevention of Stroke
- Protega Pharmaceuticals Receives FDA Approval for RoxyBond (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
- Most ERs Not Fully Equipped to Treat Pediatric Patients
- Light Physical Activity Linked to Improved Vascular Parameters in RA
- Darling Ingredients Announces Publication of Peer-Reviewed Collagen Peptides Study and its Impact on Post-Meal Blood Glucose Spikes
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions